Navigation Links
International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease

vent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra(R) and Neurontin(R), the effects of competition on our innovative products, especially Copaxone(R) sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

07292602/070813

C
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
(Date:8/21/2014)... 2014  Decision Resources Group finds that, for ... Brazil and Mexico ... prescribe long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist ... current severe cost/coverage constraints. Therefore, new brands of ... launch in these countries—which will considerably expand the ...
(Date:8/21/2014)... , Aug. 21, 2014  IBM (NYSE: IBM ... ( DESY ), a leading national research center in ... and storage of massive volumes of x-ray data. The ... on IBM software defined technology can handle more than ... and help scientists worldwide gain faster insights into the ...
(Date:8/21/2014)... , Aug. 21, 2014  Seventy-one percent of Americans believe ... is a serious public health and safety issue in ... a survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication abuse ... with this very serious health situation facing our country," ...
Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3
... , , , ... the leader in the development of devices for the percutaneous ... group of patients with the MitraClip((R)) system at the Elisabethinen ... device commercially available in the European Union which provides a ...
... HERNDON, Va., Sept. 8 BHR Pharma, ... global, Phase 3, multi-center pivotal trial ( www.synapse-trial.com ) ... product as a neuroprotective agent for treating severe traumatic brain injury ... will enroll approximately 1,200 patients with severe (Glasgow Coma Scale scores ...
Cached Medicine Technology:MitraClip(R) Therapy Introduced in Austria 2MitraClip(R) Therapy Introduced in Austria 3BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury 2
(Date:8/21/2014)... -- Not only is eating better and exercising healthy for ... dollars a year, a new study finds. The study, ... at Wake Forest Baptist Medical Center in Winston-Salem, N.C., ... patients. Participants ranged in age from 45 ... "lifestyle change program" focused on diet and exercise, or to ...
(Date:8/21/2014)... Dennis Thompson HealthDay Reporter ... combination of therapy and antidepressants appears to best help ... reports. Four out of five people suffering from ... recovery when treated with cognitive therapy plus antidepressant medication, ... didn,t work much better than drugs alone in helping ...
(Date:8/21/2014)... 2014 A new study published this ... in disability associated with speech problems from 2001-02 to ... 15% increase in disability associated with hearing problems. The ... numbers of children who are experiencing communication disorders, according ... , On a broader level, the new study, ...
(Date:8/21/2014)... Many primary care physicians in rural communities do ... (IPV), according to Penn State medical and public ... such violence have limited resources if they seek ... to help women," said Jennifer S. McCall-Hosenfeld, a ... and public health sciences, Penn State College of ...
(Date:8/21/2014)... New York (PRWEB) August 21, 2014 ... blood thinner caused patients to suffer uncontrollable internal bleeding ... courts, Bernstein Liebhard LLP reports. According to court documents, ... in U.S. District Court, Easter District of New York ... due to a bleeding event that was allegedly caused ...
Breaking Medicine News(10 mins):Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4
... , , EDEN PRAIRIE, Minn., July 14 ... by Elton John, Billy Crystal, Tony Bennett, and Gladys Knight ... the gift of hearing, raising more than $5 million to ... Hearing Foundation hosted its Ninth Annual "So the World May ...
... change disease from fatal to chronic, researcher says , ... a network of mutated genes and gene processes that, ... type of brain tumor. , "There is not a ... tumors," explained Dr. Markus Bredel, co-author of two related ...
... , , , , ... HLTH ) and its approximately 83% owned subsidiary, WebMD Health Corp. (Nasdaq: ... results for the three months ended June 30, 2009 at approximately 4:00 pm ... at 4:45 pm (ET) on that day to discuss those results. ...
... July 14 Warner Chilcott Limited (Nasdaq: WCRX ) announced ... to the market opening on Friday, August 7, 2009. , ... the Company will host a conference call for all interested parties on ... results. To participate in the call, please dial (888) 208-1812 in the ...
... , CHICAGO, July 14 Earlier today a ... ruling in Zbaraz v. Madigan, a case considering the constitutionality of the ... predecessors -- had long been enjoined from enforcement until today,s ruling. The ... for the ACLU of Illinois : , ...
... ... for surgeon general. , ... Washington, DC (Vocus) June 14, 2009 --    U.S. African Chamber Of Commerce ... physician has been an advocate for universal care, and is expected to have a ...
Cached Medicine News:Health News:Elton John, Billy Crystal, Tony Bennett, and Gladys Knight Help Starkey Hearing Foundation Raise More than $5 Million at Annual Fundraiser 2Health News:Elton John, Billy Crystal, Tony Bennett, and Gladys Knight Help Starkey Hearing Foundation Raise More than $5 Million at Annual Fundraiser 3Health News:Gene Connections Key to Brain Tumor Growth 2Health News:Gene Connections Key to Brain Tumor Growth 3Health News:HLTH and WebMD Announce Second Quarter Earnings Release Date and Conference Call 2Health News:U.S. African Chamber Of Commerce Congratulates U.S. on New Surgeon General, May Improve Health Care for Middle Income Families 2Health News:U.S. African Chamber Of Commerce Congratulates U.S. on New Surgeon General, May Improve Health Care for Middle Income Families 3
... The Nightingale Monitoring System™ expands hospital-grade monitoring ... of subacute care and disease state management. ... ability to encompass a full range of ... patients inside the hospital, to periodic monitoring ...
... FlexNet adds wireless capability to ... This expands the Flexible Monitoring concept ... patient information from anywhere to anywhere. ... ambulatory wireless monitors and hardwired and ...
... Wireless Propaq CS makes ... the Propaq CS even ... with Symbol Technologies, the ... into wireless ethernet Local ...
... The original Welch Allyn ... excellent choice for clinical areas ... Simple and straightforward to use, ... noninvasive blood pressure, and optional ...
Medicine Products: